Salbutamol and Formoterol Attenuate Okadaic Acid-Induced Cytotoxicity in Undifferentiated PC-12 Cells: Evidence for a β2-Adrenergic Receptor-Independent Protective Component
Open Access
- 29 May 2026
- journal article
- research article
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (6) , 571
Abstract
β2-adrenergic receptor (β2-AR) agonists have been implicated in neuroprotection, yet their mechanisms remain obscure. We examined whether salbutamol (SA, short-acting) or formoterol (FO, long-acting) protect PC-12 cells from okadaic acid (OA), and evaluated receptor dependence, antioxidant capacity, and apoptotic signaling. Viability was quantified with crystal violet and MTT assays. OA reduced viability to approximately 60%, and SA or FO (0.1–10 µM) improved survival, which reached 76–83% at 10 µM (p < 0.05). β2-AR blockage with ICI-118,551, and ADRB2 mRNA knockdown did not abolish protection by FO or SA, suggesting a possible β2-AR-independent protective component. However, as knockdown was not confirmed at the protein level and signaling was not directly assessed, the evidence remains provisional. FO, but not SA, exhibited direct antioxidant activity in the DPPH assay, but both at 50 μΜ lowered H2O2-induced intracellular reactive oxygen species (from 167.9% to baseline, p < 0.05). Both compounds reduced the OA-induced expression of selected pro-apoptotic transcripts, although these mRNA data do not establish the functional inhibition of apoptosis. FO reduced fold change relative to untreated control from 5.8 to 2.6 for Bax, and 6.4 to 3.4 for Bak, whereas SA achieved a significant reduction only for Bax, from 5.8 to 4.4. Taken together, SA and FO offer a partial protection to PC-12 cells from OA cytotoxicity through pathways suggesting a β2-AR-independent protective component, with FO showing additional antioxidant properties and a reduced expression of selected pro-apoptotic transcripts. These findings provide preliminary evidence that select β2 agonists may exert cytoprotective effects that are consistent with, but do not establish, a receptor-independent component. These findings warrant further protein-level and functional validation.Keywords
This publication has 26 references indexed in Scilit:
- Formoterol attenuated mitochondrial dysfunction in rotenone-induced Parkinson's disease in a rat model: Role of PINK-1/PARKIN and PI3K/Akt/CREB/BDNF/TrKB axisInternational Immunopharmacology, 2023
- Beta-blockers and salbutamol limited emotional memory disturbance and damage induced by orchiectomy in the rat hippocampusLife Sciences, 2019
- Targeting central β2 receptors ameliorates streptozotocin-induced neuroinflammation via inhibition of glycogen synthase kinase3 pathway in miceProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2018
- Salbutamol inhibits ubiquitin-mediated survival motor neuron protein degradation in spinal muscular atrophy cellsBiochemistry and Biophysics Reports, 2015
- Aβ Influences Cytoskeletal Signaling Cascades with Consequences to Alzheimer’s DiseaseMolecular Neurobiology, 2014
- Formoterol, a Long-Acting β2 Adrenergic Agonist, Improves Cognitive Function and Promotes Dendritic Complexity in a Mouse Model of Down SyndromeBiological Psychiatry, 2014
- Regulation of Akt-mTOR, ubiquitin-proteasome and autophagy-lysosome pathways in response to formoterol administration in rat skeletal muscleThe International Journal of Biochemistry & Cell Biology, 2013
- Okadaic acid induced neurotoxicity: An emerging tool to study Alzheimer's disease pathologyNeuroToxicology, 2013
- Inhibition of LTP by beta-amyloid is prevented by activation of β2 adrenoceptors and stimulation of the cAMP/PKA signalling pathwayNeurobiology of Aging, 2009
- Cytoskeletal pathologies of Alzheimer diseaseCell Motility, 2009